Nucleic Acid Aptamers Market to Reach USD 1.2 Billion by 2034: Unique Applications in Drug Delivery & Personalized Medicine Driving Growth | TMR
The unique applications of nucleic acid aptamers and their expanding properties across various sectors is fueling the nucleic acid aptamers market growth. Aptamers are being explored in drug delivery systems, personalized medicines, biomarker discovery, and biosensors.
WILMINGTON, Del., July 29, 2024 /PRNewswire/ -- The nucleic acid aptamers market is poised for remarkable growth in the coming decade. TMR forecasts the industry to register a staggering 17.2% CAGR from 2024 to 2034. By the conclusion of this forecast period, a valuation of US$ 1.2 billion is expected to be realized.
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
Since their discovery in the 1990s, several attempts have been made to utilize aptamers as clinical agents for diseases such as AIDS and macular degeneration. It is important to note that the first aptamer-based therapeutic to receive U.S. FDA approval was Macugen (Pegaptanib), that acts as a selective antagonist of vascular endothelial growth factor (VEGF) and is indicated for the treatment of patients suffering from neovascular age-related macular degeneration.
With the surging prevalence of chronic disorders such as cancer, diabetes and cardiovascular conditions, the demand for highly efficient diagnostic and therapeutic strategies is rising. In this context, in 2022, global cancer statistics suggest that nearly 20 million new cases of cancer were reported while the cancer-related mortality toll stood at 9.7 million.
Request for sample PDF copy of report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1330
Aptamers are more effective than the conventional approaches used for cancer therapy. The development of aptamers and potential conjugates has made it simple and extremely efficient to distribute medications in a targeted and selective manner.
Recent advancements in SELEX (Systematic Evolution of Ligands through Exponential Enrichment) methods have enabled the screening and filtering of aptamer probes with extremely high specificity to bind to targets, from a library of 10(13) to 10(16) single-stranded RNA or DNA molecules.
Key Takeaways from the Market Study
-- The nucleic acid aptamers market is forecast to total US$ 245.4 million
in 2024.
-- From 2024 to 2034, the market for nucleic acid aptamers is slated to
expand nearly 5x.
-- By indication, nucleic acid aptamers are expected to be used extensively
for ophthalmology.
-- DNA aptamers are anticipated to remain in high demand throughout the
forecast period.
-- Disease recognition to emerge as an important application area for
nucleic acid aptamers.
-- Nucleic acid aptamers are expected to be used widely by
biopharmaceutical companies.
Market Drivers and Trends
-- Increase in prevalence of chronic and infectious diseases is anticipated
to drive the nucleic acid aptamer market growth during the forecast
period. Chronic diseases such as cancer, diabetes, and cardiovascular
diseases, as well as infectious diseases including HIV, hepatitis, and
emerging viral infections, require precise and early diagnosis for
effective treatment.
-- Nucleic acid aptamers, with their high specificity and affinity for
target molecules, are being developed for use in advanced diagnostic
assays that can detect diseases at earlier stages with greater accuracy.
Unlock Growth Potential in Your Industry! Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1330
Region-wise Analysis
-- The United States is expected to be a major hub for nucleic acid aptamer
sales in the coming decade. This is attributed to the fact that the
country is an emerging hub for innovations in the pharmaceutical and
biological spaces.
-- Significant investments in research and development in the region have
propelled advancements in aptamer technology, including improved
selection methods, enhanced binding affinities, and novel applications
in drug delivery and diagnostics.
-- Regulatory bodies such as the FDA in the U.S. play a vital role in
shaping the nucleic acid aptamer market, providing guidance and approval
pathways for aptamer-based products, ensuring safety, efficacy, and
compliance with regulatory standards. This boosts nucleic acid aptamers
market value and commercialization.
-- Various product approvals associated with ophthalmology are expected to
drive market progress in North America. For instance, in August 2023,
FDA approved the second RNA aptamer, Izervay for treatment of geographic
atrophy (GA) secondary to age-related macular degeneration.
Nucleic Acid Aptamers Market Report Scope:
Report Coverage
Details
Forecast Period
2024-2034
Base Year
2020-2022
Size in 2023
US$ 219.9 Mn
Forecast (Value) in 2034
US$ 1.2 Bn
Growth Rate (CAGR) 17.2 %
No. of Pages
174 Pages
Segments covered By Type, By Application, By Indication, By Region,
By End-user
Competitive Landscape
The global market for nucleic acid aptamers is characterized by the presence of a large number of players. This renders the landscape highly fragmented and competitive. Market players are leveraging the potential of collaborations to introduce cutting-edge product lines.
Besides collaborations, players are vying for the top space with regards to obtaining licenses and certifications. Seeking approvals from regulatory authorities provides them with an opportunity to expand their product base and reach a wider target audience.
Key Market Players Profiled
-- Aptagen Labs
-- Aptamer Group
-- Base Pair Biotechnologies
-- NeoVentures Biotechnology Inc.
-- Aptamer Sciences Inc.
-- SomaLogic Operating Co. Inc.
-- AptaTargets SL.
-- Aptus Biotech S.L.
-- Other Prominent Players
Prominent Market Developments
-- In February 2023, Aptamer Group, a company which focuses on developing
innovative novel binders across its Optimer-based platform, revealed a
new link-up with BaseCure Therapeutics. The partnership will primarily
concentrate on emerging Optimer-targeted gene therapies.
-- In October 2022, QIAGEN N.V., announced certification of its leading
in-vitro diagnostic (IVD) kit and its fully automated NeuMoDx platforms
under the European Union's new In-Vitro Diagnostic Medical Devices
Regulation (IVDR), replacing the previous IVDD rules since May.
-- The ipsogen JAK2 RGQ PCR kit used for myeloproliferative neoplasms
(MPN), a certain type of blood cancer, is now QIAGEN's first IVD kit
with IVDR CE-marking under Class C.
Key Segments Covered
Type
-- DNA Aptamer
-- RNA Aptamer
-- XNA Aptamer
Application
-- Drug Delivery
-- Anti-viral Therapy
-- Pathogen Recognition
-- Disease Recognition
-- Stem Cell Markers
-- Others
Indication
-- Viral Infection
-- Cancer
-- Ophthalmology
-- Others
End User
-- Biopharmaceutical Companies
-- Diagnostic Centers
-- CROs
-- Others
Region
-- North America
-- Europe
-- Asia Pacific
-- Latin America
-- Middle East & Africa
Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=1330<ype=S
More Trending Reports by Transparency Market Research -
-- Healthcare Automation Market - The Global Healthcare Automation Market
Size Worth USD 88.9 Bn in 2028 Growing at a CAGR of 8.4%, TMR Study
-- Durable Medical Equipment (DME) Market - The Global Durable Medical
Equipment Market to Reach US$ 261 Bn by 2027, TMR Study
-- Lucid Dreaming Devices Market - The Global Lucid Dreaming Devices Market
is expected reach US$ 196.8 Million by the end of 2034
-- Low Endotoxin Gelatin Market - The Global Low Endotoxin Gelatin Market
is expected to grow at a CAGR of 6.4% from 2024 to 2034.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube
Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/nucleic-acid-aptamers-market-to-reach-usd-1-2-billion-by-2034-unique-applications-in-drug-delivery--personalized-medicine-driving-growth--tmr-302208436.html
SOURCE Transparency Market Research
